Article Information
History
- July 6, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 6, 2021 - 10:37).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Matthias B. Moor1,
- Franziska Suter-Riniker2,
- Michael P. Horn3,
- Daniel Aeberli4,
- Jennifer Amsler4,
- Burkhard Möller4,
- Linet M. Njue5,
- Cesare Medri5,
- Anne Angelillo-Scherrer5,
- Luca Borradori6,
- Susanne Radonjic-Hoesli6,
- Andrew Chan7,
- Robert Hoepner7,
- Vera Ulrike Bacher5,
- Laila-Yasmin Mani1,
- Joseena Mariam Iype3,
- Cédric Hirzel2,
- Britta Maurer4,* and
- Daniel Sidler1,*,†
- 1Department of Nephrology and Hypertension, Inselspital, Bern University Hospital and Department of Biomedical Research, University of Bern, Bern, Switzerland
- 2Department of Infectious Diseases, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- 3Department of Clinical Chemistry, Inselspital University Hospital, Bern, Switzerland
- 4Department of Rheumatology and Immunology, Inselspital, Bern University Hospital and Department of Biomedical Research, University of Bern, Bern, Switzerland
- 5Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 6Department of Dermatology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- 7Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- ↵†Correspondence to: PD Dr. med. et phil. Daniel Sidler, Inselspital, Bern University Hospital, Department of Nephrology and Hypertension, Freiburgstrasse 15, 3010 Bern, Switzerland, email: daniel.sidler{at}insel.ch, +41 31 632 31 44
↵* contributed equally
Posted July 06, 2021.
Humoral and cellular responses to mRNA vaccines against SARS-CoV2 in patients with a history of CD20-B-cell depleting therapy
